Asklepios BioPharmaceutical

Gene therapy
#Asklepios BioPharmaceutical #Gene therapy #Heart failure #Phase II trial

First European participant in heart failure gene therapy trial

AskBio announced that the first participant has been randomised in Europe in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II clinical trial of AB-1002 for the treatment of congestive heart failure (CHF).  GenePHIT is an adaptive, double-blind, placebo-controlled, randomised, multicentre trial to evaluate the… Read More

#News

Gene therapy
#Asklepios BioPharmaceutical #Bayer #Belief BioMed #Collaboration #Gene therapy

AskBio and Belief BioMed explore potential new gene therapies

Bayer AG and Asklepios BioPharmaceutical (AskBio) have announced a new strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. Under the terms of the contract, the companies will combine efforts and experience in gene therapy technology to explore potential therapies in… Read More

#Business & Investment #News

Gene therapy
#Asklepios BioPharmaceutical #FDA #Gene therapy #MHRA #Neurodegenerative disorders #Parkinson's

US and UK fast track designations for Parkinson’s gene therapy

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency… Read More

#News #Regulatory

Heart
#Asklepios BioPharmaceutical #Cardiovascular disease #Gene therapy #Heart failure #Phase II trial

One-time gene therapy for heart failure moves to Phase II trial

Gene therapy company Asklepios BioPharmaceutical (AskBio, a subsidiary of Bayer) has announced plans to initiate a Phase II trial of gene therapy AB-1002 for the treatment of congestive heart failure (CHF). GenePHIT (Gene PHosphatase Inhibition Therapy) will evaluate the safety and efficacy of a single intracoronary… Read More

#News

Heart monitor
#Asklepios BioPharmaceutical #Cardiovascular disease #Gene therapy #Heart failure #Phase I trial

One-time gene therapy could change treatment of heart failure

Asklepios BioPharmaceutical (AskBio), a gene therapy subsidiary of Bayer, has presented first-in-human data from a Phase I trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with congestive heart failure (CHF). The data were shared at the American Heart Association Scientific Sessions, which… Read More

#Editor's Choice #News